Pharmacokinetics of Tedizolid Following Oral Administration: Single and Multiple Dose, Effect of Food, and Comparison of Two Solid Forms of the Prodrug

Tedizolid Phosphate vs Linezolid for Treatment of Acute Bacterial Skin and Skin Structure Infections

(2013) Philippe Prokocimer et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Activity of Tedizolid Phosphate (TR-701) in Murine Models of Infection with Penicillin-Resistant and Penicillin-Sensitive Streptococcus pneumoniae

(2012) Sunghak Choi et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In VitroActivity and Microbiological Efficacy of Tedizolid (TR-700) against Gram-Positive Clinical Isolates from a Phase 2 Study of Oral Tedizolid Phosphate (TR-701) in Patients with Complicated Skin and Skin Structure Infections

(2012) Philippe Prokocimer et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pulmonary Disposition of Tedizolid following Administration of Once-Daily Oral 200-Milligram Tedizolid Phosphate in Healthy Adult Volunteers

(2012) Seth T. Housman et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Comparative Efficacies of Human Simulated Exposures of Tedizolid and Linezolid against Staphylococcus aureus in the Murine Thigh Infection Model

(2012) R. A. Keel et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

ComparativeIn VivoEfficacies of Epithelial Lining Fluid Exposures of Tedizolid, Linezolid, and Vancomycin for Methicillin-Resistant Staphylococcus aureus in a Mouse Pneumonia Model

(2012) Pamela R. Tessier et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

The Clinical Significance of Vancomycin Minimum Inhibitory Concentration in Staphylococcus aureus Infections: A Systematic Review and Meta-analysis

(2012) S. J. van Hal et al.   CLINICAL INFECTIOUS DISEASES

LEADER Surveillance program results for 2010: an activity and spectrum analysis of linezolid using 6801 clinical isolates from the United States (61 medical centers)

(2012) Robert K. Flamm et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Skin and soft tissue concentrations of tedizolid (formerly torezolid), a novel oxazolidinone, following a single oral dose in healthy volunteers

(2012) Martina Sahre et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

In VivoPharmacodynamics of Torezolid Phosphate (TR-701), a New Oxazolidinone Antibiotic, against Methicillin-Susceptible and Methicillin-Resistant Staphylococcus aureus Strains in a Mouse Thigh Infection Model

(2011) Arnold Louie et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Impact of Granulocytes on the Antimicrobial Effect of Tedizolid in a Mouse Thigh Infection Model

(2011) G. L. Drusano et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Discovery of torezolid as a novel 5-hydroxymethyl-oxazolidinone antibacterial agent

(2011) Weon Bin Im et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

In vitro activity of tedizolid (TR-700) against linezolid-resistant staphylococci

(2011) I. Rodriguez-Avial et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Phase 2, Randomized, Double-Blind, Dose-Ranging Study Evaluating the Safety, Tolerability, Population Pharmacokinetics, and Efficacy of Oral Torezolid Phosphate in Patients with Complicated Skin and Skin Structure Infections

(2010) P. Prokocimer et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Methicillin-resistant Staphylococcus aureus: related infections and antibiotic resistance

(2010) Stefania Stefani et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

In Vitro Activity of TR-700, the Active Ingredient of the Antibacterial Prodrug TR-701, a Novel Oxazolidinone Antibacterial Agent

(2009) R. Schaadt et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Novel Ribosomal Mutations in Staphylococcus aureus Strains Identified through Selection with the Oxazolidinones Linezolid and Torezolid (TR-700)

(2009) J. B. Locke et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Trends in the Incidence of Methicillin‐ResistantStaphylococcus aureusInfection in Children’s Hospitals in the United States

(2009) Jeffrey S. Gerber et al.   CLINICAL INFECTIOUS DISEASES

Activity of oxazolidinone TR-700 against linezolid-susceptible and -resistant staphylococci and enterococci

(2009) D. M. Livermore et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Limitations of antibiotic options for invasive infections caused by methicillin-resistant Staphylococcus aureus: is combination therapy the answer?

(2009) H. M. Nguyen et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

In Vitro Activity of TR-700, the Antibacterial Moiety of the Prodrug TR-701, against Linezolid-Resistant Strains

(2008) K. J. Shaw et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY